Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Medications used for the treatment of type 2 diabetes Slide 38 Class HbA1c Нуро- Weight change glycaemia change Metformin 1.5 No Neutral Sulfonylurea 1.5 Yes Gain Commonly prescribed products for the treatment of type 2 diabetes Contraindication/ undesired effects Kidney, liver Essentially none CVD risk factors Dosing (pr. day) Minimal 2 OADs None 1 OAD TZDS 0.5-1.4 DPP-IV inhibitors 0.6 -0.8 22 No Gain Varies 1 OAD No Neutral TBD 1-2 OAD CHF, liver None SGLT-2 inhibitors 0.5 -0.9 No Loss GLP-1 1.0 - 2.0 No Loss Long-acting insulin 1.5 - 2.5 Yes Gain Fast-acting insulin 1.5-2.5 Yes Gain Genital infections, urinary tract infections GI side effects, MTC Hypoglycaemia Hypoglycaemia Note: TG and HDL: Beneficial effect on triglycerides and HDL cholesterol; CHF: Congestive heart failure; GI: Gastro intestinal; MTC: Medullary thyroid cancer; TZD: thiazolidinediones; OAD: Oral anti- diabetic; TBD: to be defined. Sources: Adapted from: Nathan DM, et al. Diabetes Care. 2006; 29:1963-1972; Nathan DM, et al. Diabetes Care. 2007;30:753-759; Nathan DM, et al. Diabetes Care. 2008;31:173-175. ADA. Diabetes Care. 2008;31:S12-S54. WelChol PI. 1/2008. TBD 1 OAD Varies Varies TG and HDL TG and HDL 1 injection 1-4 injections changing diabetes® novo nordisk

View entire presentation